Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Replace the fabricated/missing Receipt 2 with an actual bundle entry, or remove the rodent contrast and reframe as a single-receipt (human RCT) memo with appropriate caveat.
2. If the rodent contrast is retained, add the real murine/rodent resveratrol+exercise source to the bundle so the species contrast is receipt-grounded.
3. Deduplicate or remove the unused 2019 rat IL-6 acute-exercise source or integrate it into the memo's argument.
4. Tone 'human randomized trials' (plural) down to 'a small human RCT' to match the bundle, and clarify whether the cited human evidence is a FASEB supplement or full paper.

Major issues

• Source-bundle vs. receipt mismatch: the receipt labelled as Receipt 2 ('Resveratrol and/or exercise training counteract aging-associated decline of physical endurance in aged mice') does not appear in the source bundle. The two actual bundle sources are (a) a 2019 rat acute-exercise IL-6 study (Il6 Responses to Exercise) and (b) the 2013 aged-men human RCT (the Receipt 1 source). The cited '2018 rodent mechanistic study' is not in the bundle, so the central species-contrast signal is not actually receipt-backed.
• Title/abstract claim 'human randomized trials suggest ... can be neutral or may interfere' is anchored to one human RCT (Gliemann 2013, n=27) plus one absent rodent study; the abstract's plural 'trials' is unsupported by the bundle.
• Bundle member 1 is a rat acute-exercise IL-6 study that is unused in the memo body; its presence inflates the perceived source count without supporting the bound claim.

Minor issues

• Receipt 1 description credits 2013; bundle lists the FASEB 2013 supplement DOI, but the memo abstract framing should clarify this is a conference supplement vs. the full published report.
• Cited_as 'mitochondrial biogenesis markers' and PGC-1α language for Receipt 2 cannot be verified without the source in the bundle.
• The memo does not specify that Gliemann 2013 is the canonical human blunting finding (later published in JPhysiol 2013/2014) vs. a conference abstract, which matters for strength of evidence.

Reviewer note

The memo's central novelty hook is the species/context split between a rodent resveratrol+exercise endurance/mitochondrial finding and a human RCT showing blunting. That split is potentially interesting, but the source bundle does not contain the rodent half: the two bundle entries are a 2019 rat acute-exercise IL-6 paper (unused) and the 2013 human RCT (Receipt 1). Receipt 2 as described cannot be verified against any bundle entry, so the core 'surprising' signal is not receipt-backed. Additionally, the abstract frames the human evidence with the plural 'trials' while the bundle contains one small n=27 RCT. Given that the central contrast relies on a non-bundled source, the memo needs a scope reset: either swap in a real rodent source matching Receipt 2's description, or drop the species contrast and reframe as a single-receipt human-RCT alpha with explicit limits. As submitted, claim_evidence_alignment is poor and source_grounding is materially compromised, so reject rather than revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis